Protagonist Therapeutics (PTGX) Net Margin (2017 - 2026)

Protagonist Therapeutics has disclosed Net Margin across 10 years of filings, most recently posting 6.71% for Q1 2026.

• Net Margin for Q1 2026 came in at 6.71%, up 4786.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 154.92% (down 4453.0% YoY), and the FY2025 annual result was 282.83%, down 28187.0% from the prior year.
• Net Margin came in at 6.71% for Q1 2026 at Protagonist Therapeutics, up from 596.8% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 180342.11% in Q4 2022 to a low of 4768.22% in Q2 2022.
• The 5-year median for Net Margin is 89.52% (2024), against an average of 13247.62%.
• Across the five-year window, Net Margin surged 18077041 bps in 2022 and plunged 18006876 bps in 2023, its largest moves.
• Protagonist Therapeutics' Net Margin stood at 180342.11% in 2022, then sank by 100 bps to 273.35% in 2023, then sank by 133 bps to 89.52% in 2024, then slumped by 567 bps to 596.8% in 2025, then surged by 101 bps to 6.71% in 2026.
• The last three Net Margin figures came in at 6.71% (Q1 2026), 596.8% (Q4 2025), and 834.87% (Q3 2025), per Business Quant data.